News

Astellas Pharma Inc. and Taysha Gene Therapies, Inc. announced a strategic investment to support the advancement of Taysha's adeno-associated virus (AAV) gene therapy development…
Read More...

Daiichi Sankyo received notification of acceptance by the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) of quizartinib in combination with standard…
Read More...

Kite, a Gilead Company and Refuge Biotechnologies, Inc. announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for…
Read More...

ARS Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review ARS’ New Drug Application (NDA) for neffy for the emergency treatment…
Read More...

Sumitovant Biopharma Ltd. in conjunction with parent company Sumitomo Pharma Co., Ltd. and Myovant Sciences announced today that they have entered into a definitive agreement pursuant…
Read More...

AbbVie announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active…
Read More...

HOOKIPA Pharma Inc. a company developing a new class of immunotherapies based on its proprietary arenavirus platform, announced a strategic collaboration and license agreement with…
Read More...

Corium, LLC a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Gurnet Point Capital (“Gurnet Point”), a…
Read More...

Takeda, Zedira and Dr. Falk Pharma GmbH announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac…
Read More...

Amgen announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc., a biopharmaceutical company focused on orally administered therapeutics to…
Read More...

AbbVie announced the acquisition of DJS Antibodies Ltd ("DJS"), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target…
Read More...

Novavax, Inc. announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to…
Read More...

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple…
Read More...

Zymeworks Inc. announced that management will host a conference call and webcast to discuss Zymeworks has entered into an exclusive licensing agreement for zanidatamab, a HER2-targeted…
Read More...

Telesis Bio and Cellibre announced initiation of work under a collaboration to optimize the development and validation of Telesis Bio’s BioXp Digital-to-Biological Converter (DBC)…
Read More...

Ginkgo Bioworks and Zymergen announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform…
Read More...

PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, announced the closing of a $35 million Series A financing…
Read More...

Ayala Pharmaceuticals, Inc. (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and…
Read More...

Charles River Laboratories International, Inc. and Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases,…
Read More...

Verseon International Corporation, the company leading a technology-driven transformation of the pharmaceutical industry, announces that it has acquired Edammo, Inc. Verseon has…
Read More...